Significance of Bcl-2 and Bcl-6 immunostaining in B-Non Hodgkin’s lymphoma

Hematology Reports

Volumn 3, Issue 3, 2011, Pages

  Mahmoud, Hanan Mohamed ^a   Nabil El Sakhawy, Yasmin ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Bcl 2; Bcl 6; Non Hodgkin s lymphoma

Indexed keywords

EID: 84891531979     PISSN: 20388322     EISSN: 20388330     Source Type: Journal    
DOI: 10.4081/hr.2011.e26     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin 2008;58:71-96.
2. Inamdar KV and Bueso-Ramos CE. Pathology of chronic lymphocytic leuke-mia: an update. Ann Diagn Pathol 2007; 11:363-89.
3. Staudt LM. Molecular diagnosis of the hematologic cancers. N Engl J Med 2003;348:1777.
4. Iqbal J, Neppalli VT, Wright G, et al. BCL-2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:961-8.
5. Hsi ED and Yegappan S. Lymphoma immunophenotyping: a new era in paraf-fin-section immunohistochemistry. Adv Anat Pathol 2001;8:218-39.
6. Bilalovic N, Blystad AK, Golouh R, et al. Expression of Bcl-6 and CD10 protein is associated with longer overall survival and time to treatment failure in follicular lym-phoma. Am J Clin Pathol 2004;121:34-42.
7. De Leval L and Harris NL. Variability in immunophenotype in diffuse large B-cell lymphoma and its clinical relevance. Histopathology 2003;43:509-28.
8. Höller S, Horn H, Lohr A, et al. A cytomor-phological and immunohistochemical profile of aggressive B-cell lymphoma: high clinical impact of a cumulative immuno-histochemical outcome predictor score. J Hematop 2009;2:187-94.
9. Linderoth J, Jerkeman M, Cavallin-Ståhl E, et al. Immunohistochemical expression of CD23 and CD40 may identify prognostical-ly favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study. Clin Cancer Res 2003;9:722-8.
10. Hiddemann W, Kneba M and Dreyling M. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage fol-licular lymphoma compared with therapy with CHOP alone. Blood 2005;106:3725-32.
11. Horvath B, Demeter J, Eros N, et al. Intravascular large B-cell lymphoma: Remission after rituximab-cyclophos-phamide, doxorubicin, vincristine, and prednisolone chemotherapy. J Am Acad Dermatol 2009;61:885-8.
12. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-86.
13. Hampson FA and Shaw AS. Response assessment in lymphoma. Clin Radiol 2008;63:125-35.
14. Elis A, Blickstein D, Klein O, et al. Detection of relapse in non-Hodgkin’s lym- phoma: Role of routine follow-up studies. Am J Hematol 2002;69:41-4.
15. Papakonstantinous G, Verbeke C, Hastka J, et al. Bcl-2 expression in non-Hodgkin’s lymphomas is not associated with Bcl-2 gene rearrangements. Brit J Haemat 2001;113:383-90.
16. Ben-Ezra JM, King BE, Harris AC, et al. Staining for Bcl-2 protein helps to distin-guish benign from malignant lymphoid aggregates in bone marrow biopsies. Mod Pathol 1994;7:560-4.
17. West RB, Warnke RA and Natkunam Y. The usefulness of immunohistochemistry in the diagnosis of follicular lymphoma in bone marrow biopsy specimens. Am J Clin Pathol 2002;117:636-43.
18. Llanos M, Alvarez-Argüelles H, Alemán R, et al. Prognostic significance of Ki-67 nuclear proliferative antigen, Bcl-2 pro-tein, and p53 expression in follicular and diffuse large B-cell lymphoma. Med Oncol 2001;18:15-22.
19. Navratil E, Gaulard P, Kanavaros P, et al. Expression of the Bcl-2 protein in B-cell lymphomas arising from mucosa-associat-ed lymphoid tissue. J Clin Pathol 1995;48:18-21.
20. Hadzi-Pecova L, Petrusevska G and Stojanovic A. Non-Hodgkin's lymphomas: immunologic prognostic studies. Prilozi 2007;28: 39-55.
21. Hermine O, Haioun C, Lepage E, et al. Prognostic significance of Bcl-2 protein expression in aggressive non-Hodgkin’s lymphoma. Groupe d’Etude des Lymphomes de l’Adulte (GELA). Blood 1996;87:265-72.
22. Tang SC, Visser L, Hepperle B, et al. Clinical significance of Bcl-2-MBR gene rearrangement and protein expression in diffuse large-cell non-Hodgkin's lym-phoma: an analysis of 83 cases. J Clin Oncol 1994;12:149-54.
23. Miller TP, Levy N, Bailey NP, et al. The Bcl-2 gene translocation t(14;18) identifies a subgroup of patients with diffuse large cell lymphoma having an indolent clinical course with late relapse. Proc Am Soc Clin Oncol 1994;13:370.
24. Piris MA, Pezzella F, Martinez-Montero JC, et al. p53 and Bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time. Br J Cancer 1994;69:337-41.
25. Hallack Neto AE, Siqueira SA, et al. Bcl-2 protein frequency in patients with high-risk diffuse large B-cell lymphoma. Sao Paulo Med J 2010;128:14-7.
26. Barrans SL, O’Connor SJM, Evans PAS, et al. Rearrangement of the BCL-6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lym-phoma. Br J Haematol 2002;117:322-32.
27. Lossos IS, Alizadeh AA, Eisen MB, et al. Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. Proc Natl Acad Sci USA 2000;97:10209-13.
28. Berglund M, Thunberg U, Amini RM, et al. Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod Pathol 2005;18:1113-20.
29. Dogan A, Bagdi E, Munson P, et al. CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lym-phomas. Am J Surg Pathol 2000;24:846-52.
30. Colomo L, López-Guillermo A, Perales M, et al. (2003): Clinical impact of the differentiation profile assessed by immunopheno-typing in patients with diffuse large B-cell lymphoma. Blood 2003;101:78-84.
31. Chuang SS, Huang WT, Hsieh PP, et al. Mantle cell lymphoma in Taiwan: clinico- pathological and molecular study of 21 cases including one cyclin D1-negative tumor expressing cyclin D2. Pathol Int 2006;56:440-8.
32. Gualco G, Weiss LM, Harrington WJ Jr, et al. BCL-6, MUM1, and CD10 expression in mantle cell lymphoma. Appl Immunohis-tochem Mol Morphol 2010;18:103-8.